Key result
Sotagliflozin was evaluated for its cardiovascular efficacy and safety in a trial of 1,222 patients with type 2 diabetes and recent decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Discusses the accumulating evidence for cardiovascular benefits of SGLT2 inhibitors, specifically highlighting sotagliflozin trials in patients with diabetes and recent worsening heart failure.
Evidence for the cardiovascular benefits of sodium–glucose cotransporter 2 (SGLT2) inhibitors continues to accumulate. Most recently, Bhatt et al. performed two randomized trials to investigate the cardiovascular effects of sotagliflozin; their findings are now reported in the Journal.1,2 Sotagliflozin, unlike other drugs in this class, also has an inhibitory effect on intestinal SGLT1, a related sodium–glucose cotransporter. The first trial, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF),1 involving 1222 participants with type 2 diabetes who had a very recent episode of decompensated heart failure, was designed to determine the efficacy and safety of sotagliflozin in preventing . . .
No takes yet. Share an insight, caveat, or question.
Brosius et al. (2021) conducted an editorial in Type 2 diabetes and recent worsening heart failure (n=1,222). Sotagliflozin was evaluated. Sotagliflozin was evaluated for its cardiovascular efficacy and safety in a trial of 1,222 patients with type 2 diabetes and recent decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: